Results 171 to 180 of about 4,744 (194)
Some of the next articles are maybe not open access.
Cancer Research, 2018
Abstract 5-Fluorouracil (5-FU) is a cornerstone therapy for the treatment of several aggressive tumors. However, nearly 1/3 of patients receiving 5-FU experience severe (grade 3+) adverse 5-FU toxicity. Genetic variations in dihydropyrimidine dehydrogenase (DPD; DPYD gene) are major contributors of 5-FU toxicity.
Shikshya Shrestha +5 more
openaire +1 more source
Abstract 5-Fluorouracil (5-FU) is a cornerstone therapy for the treatment of several aggressive tumors. However, nearly 1/3 of patients receiving 5-FU experience severe (grade 3+) adverse 5-FU toxicity. Genetic variations in dihydropyrimidine dehydrogenase (DPD; DPYD gene) are major contributors of 5-FU toxicity.
Shikshya Shrestha +5 more
openaire +1 more source
Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US
Supportive Care in CancerPatients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment DPYD testing is standard of care in many countries, but not the United States (US).
Tabea Tracksdorf +9 more
openaire +2 more sources
Frequency of DPYD gene variants and phenotype inference in a Southern Brazilian population
Annals of Human Genetics, 2022Mariana Rodrigues Botton, Ursula Matte
exaly
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
ESMO Open, 2023Niels Herluf Paulsen +2 more
exaly
Translating DPYD Genotype into DPD Phenotype: Using the DPYD Gene Activity Score
Pharmacogenomics, 2015Jan H M Schellens +2 more
exaly